Nicholas Jon Virca is the Pres & CEO at Inhibitor Therapeutics.
As the Pres & CEO of Inhibitor Therapeutics, the total compensation of Mr Virca at Inhibitor Therapeutics is $144,684. There are no executives at Inhibitor Therapeutics getting paid more.
Mr Virca is 75, he's been the Pres & CEO of Inhibitor Therapeutics since . There are no older and 1 younger executives at Inhibitor Therapeutics.
Nicholas's mailing address filed with the SEC is 449 SOUTH 12TH STREET, UNIT 1705, , TAMPA, FL, 33602.
Over the last 5 years, insiders at Inhibitor Therapeutics have traded over $0 worth of Inhibitor Therapeutics stock and bought 13,500 units worth $945 . The most active insiders traders include James A Mcnulty, W. Mark Watson und Samuel P Jr Sears. On average, Inhibitor Therapeutics executives and independent directors trade stock every 0 days with the average trade being worth of $1,080. The most recent stock trade was executed by Garrison J. Hasara on 2 December 2019, trading 13,500 units of INTI stock currently worth $945.
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
Inhibitor Therapeutics executives and other stock owners filed with the SEC include: